- Home
- JAZZ vs IDA Comparison
JAZZ vs IDA Comparison
Compare JAZZ & IDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- IDA
- Stock Information
- Founded
- JAZZ 2003
- IDA 1915
- Country
- JAZZ Ireland
- IDA United States
- Employees
- JAZZ N/A
- IDA N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- IDA Electric Utilities: Central
- Sector
- JAZZ Health Care
- IDA Utilities
- Exchange
- JAZZ Nasdaq
- IDA Nasdaq
- Market Cap
- JAZZ 6.7B
- IDA 6.3B
- IPO Year
- JAZZ 2007
- IDA N/A
- Fundamental
- Price
- JAZZ $110.27
- IDA $117.40
- Analyst Decision
- JAZZ Strong Buy
- IDA Buy
- Analyst Count
- JAZZ 12
- IDA 7
- Target Price
- JAZZ $183.08
- IDA $122.86
- AVG Volume (30 Days)
- JAZZ 651.1K
- IDA 418.1K
- Earning Date
- JAZZ 07-30-2025
- IDA 07-31-2025
- Dividend Yield
- JAZZ N/A
- IDA 2.93%
- EPS Growth
- JAZZ 49.21
- IDA 12.96
- EPS
- JAZZ 7.51
- IDA 5.63
- Revenue
- JAZZ $4,064,808,000.00
- IDA $1,810,154,000.00
- Revenue This Year
- JAZZ $6.05
- IDA $5.33
- Revenue Next Year
- JAZZ $4.68
- IDA $10.24
- P/E Ratio
- JAZZ $14.72
- IDA $20.90
- Revenue Growth
- JAZZ 5.76
- IDA 1.37
- 52 Week Low
- JAZZ $95.49
- IDA $93.16
- 52 Week High
- JAZZ $148.06
- IDA $120.84
- Technical
- Relative Strength Index (RSI)
- JAZZ 52.75
- IDA 58.08
- Support Level
- JAZZ $109.27
- IDA $113.99
- Resistance Level
- JAZZ $112.70
- IDA $118.84
- Average True Range (ATR)
- JAZZ 2.72
- IDA 1.72
- MACD
- JAZZ 0.42
- IDA 0.37
- Stochastic Oscillator
- JAZZ 67.81
- IDA 75.09
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About IDA IDACORP Inc.
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The companys only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education.